rNAPc2. Nuvelo.
Recombinant nematode anticoagulant protein-2 (rNAPc2) is an antithrombotic protein under development by Nuvelo as a potential therapeutic agent for the treatment of major acute cardiovascular disease such as unstable angina and myocardial infarction. Phase II clinical trials were ongoing in January 2004, although development for deep vein thrombosis had been suspended by Dendreon due to a requirement for a partner to assist with additional phase II clinical trials.
Mungall
Dennis
D
College of Pharmacy, Ohio State University, 500 W Twelfth Ave, Columbus, OH 43210-1291, USA. Thertch@aol.com
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005343:Fibrinolytic Agents / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D015801:Helminth Proteins / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D011994:Recombinant Proteins / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D020246:Venous Thrombosis / Q000188:drug therapy
D005343:Fibrinolytic Agents; D015801:Helminth Proteins; D011994:Recombinant Proteins; C400226:anti-coagulant protein C2, Ancylostoma caninum